While additional experiments are needed to elucidate the mechanism of action of GREB1, the prolonged survival of mice when GREB1 is suppressed provides initial evidence, suggesting that targeting GREB1 could have therapeutic efficacy in ovarian cancer. This evidence concerns the gene GREB1 and ovarian carcinoma.